These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 3602747

  • 1. Depression of toxic effects of anticancer agents by selenium or pretreatment with metallothionein inducers.
    Imura N, Naganuma A, Satoh M, Koyama Y.
    J UOEH; 1987 Mar 20; 9 Suppl():223-9. PubMed ID: 3602747
    [No Abstract] [Full Text] [Related]

  • 2. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination.
    Satoh M, Naganuma A, Imura N.
    Cancer Chemother Pharmacol; 1988 Mar 20; 21(2):176-8. PubMed ID: 3349566
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of preinduction of metallothionein synthesis on clastogenicity of anticancer drugs in mice.
    Nakagawa I, Nishi E, Naganuma A, Imura N.
    Mutat Res; 1995 Sep 20; 348(1):37-43. PubMed ID: 7565913
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Protective effect of bismuth nitrate against injury to the bone marrow by gamma-irradiation in mice: possible involvement of induction of metallothionein synthesis.
    Miura N, Satoh M, Imura N, Naganuma A.
    J Pharmacol Exp Ther; 1998 Sep 20; 286(3):1427-30. PubMed ID: 9732407
    [Abstract] [Full Text] [Related]

  • 12. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
    Kondo Y, Himeno S, Satoh M, Naganuma A, Nishimura T, Imura N.
    Cancer Chemother Pharmacol; 2004 Jan 20; 53(1):33-8. PubMed ID: 14530870
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Induction of renal metallothionein allows increasing dose of an extensively used antitumor drug, cis-diamminedichloroplatinum.
    Imura N, Naganuma A, Satoh M, Koyama Y.
    Experientia Suppl; 1987 Jan 20; 52():655-60. PubMed ID: 2959559
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis.
    Satoh M, Cherian MG, Imura N, Shimizu H.
    Cancer Res; 1994 Oct 15; 54(20):5255-7. PubMed ID: 7923149
    [Abstract] [Full Text] [Related]

  • 20. Toxicological aspects of metallothionein.
    Nordberg M, Nordberg GF.
    Cell Mol Biol (Noisy-le-grand); 2000 Mar 15; 46(2):451-63. PubMed ID: 10774933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.